25 XP   0   0   10

Paradigm Biopharmaceuticals Ltd
Buy, Hold or Sell?

Let's analyse Paradigm Biopharmaceuticals Ltd together

PenkeI guess you are interested in Paradigm Biopharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Paradigm Biopharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Paradigm Biopharmaceuticals Ltd

I send you an email if I find something interesting about Paradigm Biopharmaceuticals Ltd.

Quick analysis of Paradigm Biopharmaceuticals Ltd (30 sec.)










What can you expect buying and holding a share of Paradigm Biopharmaceuticals Ltd? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.10
Expected worth in 1 year
A$-0.06
How sure are you?
32.4%

+ What do you gain per year?

Total Gains per Share
A$-0.15
Return On Investment
-56.1%

For what price can you sell your share?

Current Price per Share
A$0.27
Expected price per share
A$0.265 - A$0.335
How sure are you?
50%

1. Valuation of Paradigm Biopharmaceuticals Ltd (5 min.)




Live pricePrice per Share (EOD)

A$0.27

Intrinsic Value Per Share

A$-17.39 - A$-20.83

Total Value Per Share

A$-17.29 - A$-20.73

2. Growth of Paradigm Biopharmaceuticals Ltd (5 min.)




Is Paradigm Biopharmaceuticals Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$22m$34.5m$595.7k1.7%

How much money is Paradigm Biopharmaceuticals Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$17.2m-$10.8m-$6.3m-37.2%
Net Profit Margin-15,887.9%-178,159.4%--

How much money comes from the company's main activities?

3. Financial Health of Paradigm Biopharmaceuticals Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#517 / 1010

Most Revenue
#672 / 1010

Most Profit
#820 / 1010

Most Efficient
#992 / 1010

What can you expect buying and holding a share of Paradigm Biopharmaceuticals Ltd? (5 min.)

Welcome investor! Paradigm Biopharmaceuticals Ltd's management wants to use your money to grow the business. In return you get a share of Paradigm Biopharmaceuticals Ltd.

What can you expect buying and holding a share of Paradigm Biopharmaceuticals Ltd?

First you should know what it really means to hold a share of Paradigm Biopharmaceuticals Ltd. And how you can make/lose money.

Speculation

The Price per Share of Paradigm Biopharmaceuticals Ltd is A$0.27. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Paradigm Biopharmaceuticals Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Paradigm Biopharmaceuticals Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.10. Based on the TTM, the Book Value Change Per Share is A$-0.04 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Paradigm Biopharmaceuticals Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.09-33.8%-0.04-15.9%-0.02-7.6%-0.02-7.4%-0.01-4.6%
Usd Book Value Change Per Share-0.04-13.7%-0.02-9.2%0.013.6%0.000.5%0.000.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.04-13.7%-0.02-9.2%0.013.6%0.000.5%0.000.7%
Usd Price Per Share0.28-0.64-0.80-1.26-0.83-
Price to Earnings Ratio-0.76--7.53--11.51--30.15--28.74-
Price-to-Total Gains Ratio-7.50--12.69--8.45--43.32-47,750.44-
Price to Book Ratio4.41-6.03-8.41-9.12-9.79-
Price-to-Total Gains Ratio-7.50--12.69--8.45--43.32-47,750.44-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.176445
Number of shares5667
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.00
Usd Total Gains Per Share-0.020.00
Gains per Quarter (5667 shares)-140.238.02
Gains per Year (5667 shares)-560.9332.08
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-561-57103222
20-1122-113206454
30-1683-169309686
40-2244-22540128118
50-2805-28150160150
60-3366-33760192182
70-3926-39370225214
80-4487-44980257246
90-5048-50590289278
100-5609-56200321310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.03.00.00.0%0.011.00.00.0%0.019.00.00.0%0.032.02.00.0%0.032.02.00.0%
Book Value Change Per Share0.02.01.00.0%1.05.05.09.1%3.07.09.015.8%11.012.011.032.4%11.012.011.032.4%
Dividend per Share0.00.03.00.0%0.00.011.00.0%0.00.019.00.0%0.00.034.00.0%0.00.034.00.0%
Total Gains per Share0.02.01.00.0%1.05.05.09.1%3.07.09.015.8%11.012.011.032.4%11.012.011.032.4%

Fundamentals of Paradigm Biopharmaceuticals Ltd

About Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-04-26 09:03:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Paradigm Biopharmaceuticals Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Paradigm Biopharmaceuticals Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Paradigm Biopharmaceuticals Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Paradigm Biopharmaceuticals Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-15,887.9%+15,887.9%
TTM-15,887.9%YOY-178,159.4%+162,271.5%
TTM-15,887.9%5Y-43,671.6%+27,783.7%
5Y-43,671.6%10Y-26,218.1%-17,453.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM-15,887.9%-216.8%-15,671.1%
YOY-178,159.4%-282.3%-177,877.1%
5Y-43,671.6%-436.8%-43,234.8%
10Y-26,218.1%-597.3%-25,620.8%
1.1.2. Return on Assets

Shows how efficient Paradigm Biopharmaceuticals Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Paradigm Biopharmaceuticals Ltd to the Biotechnology industry mean.
  • -108.7% Return on Assets means that Paradigm Biopharmaceuticals Ltd generated $-1.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Paradigm Biopharmaceuticals Ltd:

  • The MRQ is -108.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -50.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-108.7%TTM-50.0%-58.7%
TTM-50.0%YOY-25.2%-24.8%
TTM-50.0%5Y-19.8%-30.1%
5Y-19.8%10Y-14.6%-5.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-108.7%-13.3%-95.4%
TTM-50.0%-12.8%-37.2%
YOY-25.2%-11.6%-13.6%
5Y-19.8%-13.8%-6.0%
10Y-14.6%-15.6%+1.0%
1.1.3. Return on Equity

Shows how efficient Paradigm Biopharmaceuticals Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Paradigm Biopharmaceuticals Ltd to the Biotechnology industry mean.
  • -144.9% Return on Equity means Paradigm Biopharmaceuticals Ltd generated $-1.45 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Paradigm Biopharmaceuticals Ltd:

  • The MRQ is -144.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -65.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-144.9%TTM-65.3%-79.6%
TTM-65.3%YOY-30.4%-34.9%
TTM-65.3%5Y-24.2%-41.1%
5Y-24.2%10Y-17.3%-6.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-144.9%-16.9%-128.0%
TTM-65.3%-16.1%-49.2%
YOY-30.4%-14.9%-15.5%
5Y-24.2%-19.3%-4.9%
10Y-17.3%-20.1%+2.8%

1.2. Operating Efficiency of Paradigm Biopharmaceuticals Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Paradigm Biopharmaceuticals Ltd is operating .

  • Measures how much profit Paradigm Biopharmaceuticals Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Paradigm Biopharmaceuticals Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Paradigm Biopharmaceuticals Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-21,339.7%+21,339.7%
TTM-21,339.7%YOY-185,937.1%+164,597.5%
TTM-21,339.7%5Y-45,985.8%+24,646.2%
5Y-45,985.8%10Y-27,478.9%-18,507.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM-21,339.7%-238.5%-21,101.2%
YOY-185,937.1%-288.4%-185,648.7%
5Y-45,985.8%-486.2%-45,499.6%
10Y-27,478.9%-628.4%-26,850.5%
1.2.2. Operating Ratio

Measures how efficient Paradigm Biopharmaceuticals Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Paradigm Biopharmaceuticals Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM213.730-213.730
TTM213.730YOY1,859.871-1,646.141
TTM213.7305Y457.333-243.603
5Y457.33310Y272.733+184.601
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM213.7303.310+210.420
YOY1,859.8713.838+1,856.033
5Y457.3335.679+451.654
10Y272.7337.823+264.910

1.3. Liquidity of Paradigm Biopharmaceuticals Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Paradigm Biopharmaceuticals Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.83 means the company has $3.83 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Paradigm Biopharmaceuticals Ltd:

  • The MRQ is 3.830. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.537. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.830TTM4.537-0.707
TTM4.537YOY5.958-1.421
TTM4.5375Y19.441-14.904
5Y19.44110Y12.945+6.496
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8303.863-0.033
TTM4.5374.169+0.368
YOY5.9585.337+0.621
5Y19.4416.122+13.319
10Y12.9456.434+6.511
1.3.2. Quick Ratio

Measures if Paradigm Biopharmaceuticals Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Paradigm Biopharmaceuticals Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 3.75 means the company can pay off $3.75 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Paradigm Biopharmaceuticals Ltd:

  • The MRQ is 3.752. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.041. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.752TTM3.041+0.711
TTM3.041YOY3.160-0.119
TTM3.0415Y10.755-7.714
5Y10.75510Y7.454+3.301
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7523.504+0.248
TTM3.0413.991-0.950
YOY3.1605.371-2.211
5Y10.7556.088+4.667
10Y7.4546.395+1.059

1.4. Solvency of Paradigm Biopharmaceuticals Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Paradigm Biopharmaceuticals Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Paradigm Biopharmaceuticals Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.25 means that Paradigm Biopharmaceuticals Ltd assets are financed with 25.0% credit (debt) and the remaining percentage (100% - 25.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Paradigm Biopharmaceuticals Ltd:

  • The MRQ is 0.250. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.206. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.250TTM0.206+0.044
TTM0.206YOY0.179+0.027
TTM0.2065Y0.107+0.099
5Y0.10710Y0.105+0.002
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2500.339-0.089
TTM0.2060.337-0.131
YOY0.1790.271-0.092
5Y0.1070.368-0.261
10Y0.1050.388-0.283
1.4.2. Debt to Equity Ratio

Measures if Paradigm Biopharmaceuticals Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Paradigm Biopharmaceuticals Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 33.3% means that company has $0.33 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Paradigm Biopharmaceuticals Ltd:

  • The MRQ is 0.333. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.261. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.333TTM0.261+0.071
TTM0.261YOY0.218+0.043
TTM0.2615Y0.129+0.132
5Y0.12910Y0.133-0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3330.392-0.059
TTM0.2610.403-0.142
YOY0.2180.335-0.117
5Y0.1290.427-0.298
10Y0.1330.461-0.328

2. Market Valuation of Paradigm Biopharmaceuticals Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Paradigm Biopharmaceuticals Ltd generates.

  • Above 15 is considered overpriced but always compare Paradigm Biopharmaceuticals Ltd to the Biotechnology industry mean.
  • A PE ratio of -0.76 means the investor is paying $-0.76 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Paradigm Biopharmaceuticals Ltd:

  • The EOD is -0.484. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.762. Based on the earnings, the company is expensive. -2
  • The TTM is -7.530. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.484MRQ-0.762+0.278
MRQ-0.762TTM-7.530+6.768
TTM-7.530YOY-11.513+3.984
TTM-7.5305Y-30.149+22.619
5Y-30.14910Y-28.741-1.408
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.484-2.300+1.816
MRQ-0.762-2.656+1.894
TTM-7.530-2.718-4.812
YOY-11.513-4.145-7.368
5Y-30.149-6.258-23.891
10Y-28.741-6.315-22.426
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Paradigm Biopharmaceuticals Ltd:

  • The EOD is -0.464. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.731. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.329. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.464MRQ-0.731+0.267
MRQ-0.731TTM-1.329+0.598
TTM-1.329YOY-3.201+1.872
TTM-1.3295Y-1,520.157+1,518.828
5Y-1,520.15710Y-857.757-662.400
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.464-2.974+2.510
MRQ-0.731-3.306+2.575
TTM-1.329-3.508+2.179
YOY-3.201-5.613+2.412
5Y-1,520.157-8.378-1,511.779
10Y-857.757-8.873-848.884
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Paradigm Biopharmaceuticals Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.41 means the investor is paying $4.41 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Paradigm Biopharmaceuticals Ltd:

  • The EOD is 2.803. Based on the equity, the company is underpriced. +1
  • The MRQ is 4.413. Based on the equity, the company is fair priced.
  • The TTM is 6.032. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.803MRQ4.413-1.609
MRQ4.413TTM6.032-1.619
TTM6.032YOY8.410-2.378
TTM6.0325Y9.121-3.089
5Y9.12110Y9.790-0.668
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.8031.914+0.889
MRQ4.4132.116+2.297
TTM6.0322.097+3.935
YOY8.4102.881+5.529
5Y9.1213.550+5.571
10Y9.7903.936+5.854
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Paradigm Biopharmaceuticals Ltd.

3.1. Funds holding Paradigm Biopharmaceuticals Ltd

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Paradigm Biopharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.057-0.038-33%0.015-483%0.002-2716%0.003-2100%
Book Value Per Share--0.0960.153-37%0.150-36%0.207-53%0.133-27%
Current Ratio--3.8304.537-16%5.958-36%19.441-80%12.945-70%
Debt To Asset Ratio--0.2500.206+21%0.179+40%0.107+133%0.105+139%
Debt To Equity Ratio--0.3330.261+27%0.218+52%0.129+158%0.133+150%
Dividend Per Share----0%-0%-0%-0%
Eps---0.140-0.066-53%-0.031-77%-0.031-78%-0.019-86%
Free Cash Flow Per Share---0.145-0.112-23%-0.047-67%-0.034-77%-0.020-86%
Free Cash Flow To Equity Per Share---0.065-0.071+10%0.041-256%-0.014-78%-0.011-83%
Gross Profit Margin--1.0051.0080%1.014-1%1.005+0%0.944+6%
Intrinsic Value_10Y_max---20.825--------
Intrinsic Value_10Y_min---17.390--------
Intrinsic Value_1Y_max---0.553--------
Intrinsic Value_1Y_min---0.542--------
Intrinsic Value_3Y_max---2.831--------
Intrinsic Value_3Y_min---2.679--------
Intrinsic Value_5Y_max---6.518--------
Intrinsic Value_5Y_min---5.949--------
Market Cap94755415.680-57%149152043.200341365158.637-56%430286097.333-65%676160239.036-78%447331234.117-67%
Net Profit Margin----158.8790%-1781.5940%-436.7160%-262.1810%
Operating Margin----213.3970%-1859.3710%-459.8580%-274.7890%
Operating Ratio---213.730-100%1859.871-100%457.333-100%272.733-100%
Pb Ratio2.803-57%4.4136.032-27%8.410-48%9.121-52%9.790-55%
Pe Ratio-0.484+36%-0.762-7.530+889%-11.513+1412%-30.149+3858%-28.741+3674%
Price Per Share0.270-57%0.4250.973-56%1.226-65%1.927-78%1.275-67%
Price To Free Cash Flow Ratio-0.464+36%-0.731-1.329+82%-3.201+338%-1520.157+207910%-857.757+117271%
Price To Total Gains Ratio-4.767+36%-7.503-12.687+69%-8.447+13%-43.317+477%47750.443-100%
Quick Ratio--3.7523.041+23%3.160+19%10.755-65%7.454-50%
Return On Assets---1.087-0.500-54%-0.252-77%-0.198-82%-0.146-87%
Return On Equity---1.449-0.653-55%-0.304-79%-0.242-83%-0.173-88%
Total Gains Per Share---0.057-0.038-33%0.015-483%0.002-2716%0.003-2100%
Usd Book Value--22087787.65635102251.919-37%34506534.226-36%47482691.273-53%30395752.550-27%
Usd Book Value Change Per Share---0.037-0.025-33%0.010-483%0.001-2716%0.002-2100%
Usd Book Value Per Share--0.0630.100-37%0.098-36%0.135-53%0.087-27%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.091-0.043-53%-0.021-77%-0.020-78%-0.012-86%
Usd Free Cash Flow---33343472.992-17090087.155-49%-5429133.250-84%-4531124.213-86%-2804611.722-92%
Usd Free Cash Flow Per Share---0.095-0.073-23%-0.031-67%-0.022-77%-0.013-86%
Usd Free Cash Flow To Equity Per Share---0.042-0.046+10%0.027-256%-0.009-78%-0.007-83%
Usd Market Cap61922664.147-57%97470860.231223082131.169-56%281191964.607-65%441870716.210-78%292330961.496-67%
Usd Price Per Share0.176-57%0.2780.636-56%0.801-65%1.259-78%0.833-67%
Usd Profit---31994305.905-17213683.610-46%-10815091.878-66%-8579525.585-73%-5166271.221-84%
Usd Revenue---9159.892-100%6328.167-100%649079.588-100%501311.056-100%
Usd Total Gains Per Share---0.037-0.025-33%0.010-483%0.001-2716%0.002-2100%
 EOD+3 -5MRQTTM+7 -25YOY+5 -275Y+5 -2710Y+4 -28

4.2. Fundamental Score

Let's check the fundamental score of Paradigm Biopharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.484
Price to Book Ratio (EOD)Between0-12.803
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.752
Current Ratio (MRQ)Greater than13.830
Debt to Asset Ratio (MRQ)Less than10.250
Debt to Equity Ratio (MRQ)Less than10.333
Return on Equity (MRQ)Greater than0.15-1.449
Return on Assets (MRQ)Greater than0.05-1.087
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Paradigm Biopharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.290
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in AUD. All numbers in thousands.

Summary
Total Assets45,039
Total Liabilities11,240
Total Stockholder Equity33,799
 As reported
Total Liabilities 11,240
Total Stockholder Equity+ 33,799
Total Assets = 45,039

Assets

Total Assets45,039
Total Current Assets41,828
Long-term Assets3,211
Total Current Assets
Cash And Cash Equivalents 33,551
Net Receivables 7,427
Other Current Assets 850
Total Current Assets  (as reported)41,828
Total Current Assets  (calculated)41,828
+/-0
Long-term Assets
Property Plant Equipment 263
Intangible Assets 2,948
Long-term Assets Other 0
Long-term Assets  (as reported)3,211
Long-term Assets  (calculated)3,211
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,922
Long-term Liabilities317
Total Stockholder Equity33,799
Total Current Liabilities
Short-term Debt 113
Accounts payable 9,986
Other Current Liabilities 823
Total Current Liabilities  (as reported)10,922
Total Current Liabilities  (calculated)10,922
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)317
Long-term Liabilities  (calculated)0
+/- 317
Total Stockholder Equity
Common Stock238,113
Retained Earnings -211,754
Accumulated Other Comprehensive Income 7,440
Other Stockholders Equity 0
Total Stockholder Equity (as reported)33,799
Total Stockholder Equity (calculated)33,799
+/-0
Other
Cash and Short Term Investments 33,551
Common Stock Shares Outstanding 299,790
Liabilities and Stockholders Equity 45,039
Net Debt -33,261
Short Long Term Debt Total 290



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-12-312023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-06-30
> Total Assets 
217
0
1,442
1,194
13,097
13,097
12,347
12,347
16,338
16,338
14,345
14,345
16,279
16,279
15,191
15,191
20,511
20,511
85,511
85,511
81,249
81,249
0
112,364
0
95,281
0
84,792
0
67,494
0
50,689
0
88,505
0
67,070
45,039
45,03967,070088,505050,689067,494084,792095,2810112,364081,24981,24985,51185,51120,51120,51115,19115,19116,27916,27914,34514,34516,33816,33812,34712,34713,09713,0971,1941,4420217
   > Total Current Assets 
0
0
0
838
0
5,351
0
4,349
6,479
6,479
4,426
4,426
6,227
6,227
5,272
5,272
10,594
10,594
82,506
82,506
77,245
77,245
108,371
108,371
91,359
91,359
80,978
80,978
63,879
63,879
47,170
47,170
85,144
85,144
63,786
63,786
41,828
41,82863,78663,78685,14485,14447,17047,17063,87963,87980,97880,97891,35991,359108,371108,37177,24577,24582,50682,50610,59410,5945,2725,2726,2276,2274,4264,4266,4796,4794,34905,3510838000
       Cash And Cash Equivalents 
0
0
0
125
0
5,266
0
2,998
5,025
5,025
2,591
2,591
6,002
6,002
2,446
2,446
9,934
9,934
72,336
78,836
70,934
70,934
0
103,922
0
85,206
0
71,035
0
54,798
0
39,674
0
83,926
0
56,333
33,551
33,55156,333083,926039,674054,798071,035085,2060103,922070,93470,93478,83672,3369,9349,9342,4462,4466,0026,0022,5912,5915,0255,0252,99805,2660125000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,500
6,500
2,696
2,696
0
746
0
746
0
46
0
232
0
46
0
0
0
46
0
0460004602320460746074602,6962,6966,5006,500000000000000000000
       Net Receivables 
20
0
21
16
30
30
1,342
1,342
1,352
1,352
1,815
1,815
33
33
2,735
2,735
456
456
3,532
3,532
3,306
3,306
3,510
3,510
3,498
3,498
8,508
8,508
7,156
7,156
6,719
6,719
265
265
6,807
6,807
7,427
7,4276,8076,8072652656,7196,7197,1567,1568,5088,5083,4983,4983,5103,5103,3063,3063,5323,5324564562,7352,73533331,8151,8151,3521,3521,3421,34230301621020
       Inventory 
0
0
0
0
0
0
0
-1,342
0
0
0
-1,815
0
0
0
-2,735
0
0
0
-3,532
0
0
0
0
0
0
0
8,487
0
0
0
0
0
0
0
46
0
04600000008,4870000000-3,532000-2,735000-1,815000-1,3420000000
   > Long-term Assets 
0
0
0
356
0
7,746
0
7,998
0
9,859
0
9,919
0
10,052
0
9,919
0
9,916
0
3,005
0
4,004
0
3,993
0
3,921
0
3,815
0
3,615
0
3,519
0
3,361
0
3,284
3,211
3,2113,28403,36103,51903,61503,81503,92103,99304,00403,00509,91609,919010,05209,91909,85907,99807,7460356000
       Property Plant Equipment 
0
0
0
0
3
3
11
11
20
20
14
14
13
13
9
9
7
7
24
24
1,022
1,022
943
943
871
871
764
764
668
668
571
571
413
413
336
336
263
2633363364134135715716686687647648718719439431,0221,022242477991313141420201111330000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
103
0
0
0
103
0
0
0
0
0
0
0
0
0
00000000010300010300000000000000000000000
       Intangible Assets 
89
0
296
356
7,743
7,743
7,988
7,988
9,839
9,839
9,905
9,905
10,039
10,039
9,910
9,910
9,909
9,909
2,981
2,981
2,982
2,982
0
2,948
0
2,948
0
2,948
0
2,948
0
2,948
0
2,948
0
2,948
2,948
2,9482,94802,94802,94802,94802,94802,94802,94802,9822,9822,9812,9819,9099,9099,9109,91010,03910,0399,9059,9059,8399,8397,9887,9887,7437,743356296089
       Long-term Assets Other 
0
0
0
-356
0
-7,746
0
-7,998
0
-9,859
0
-9,919
0
-10,052
0
-9,919
0
-9,916
0
-3,005
0
-4,004
0
0
0
103
0
0
0
-3,615
0
-3,519
0
-3,361
0
-3,284
0
0-3,2840-3,3610-3,5190-3,615000103000-4,0040-3,0050-9,9160-9,9190-10,0520-9,9190-9,8590-7,9980-7,7460-356000
> Total Liabilities 
369
0
577
585
420
420
1,117
1,117
1,633
1,633
955
955
1,362
1,362
1,327
1,327
1,151
1,151
2,705
2,705
1,973
1,973
0
4,182
0
5,832
0
6,519
0
14,575
0
8,376
0
14,839
0
13,392
11,240
11,24013,392014,83908,376014,57506,51905,83204,18201,9731,9732,7052,7051,1511,1511,3271,3271,3621,3629559551,6331,6331,1171,1174204205855770369
   > Total Current Liabilities 
369
0
577
585
420
420
1,117
1,117
1,633
1,633
955
955
1,362
1,362
1,327
1,327
1,151
1,151
2,705
2,705
1,159
1,159
3,365
3,365
5,059
5,059
5,793
5,793
13,961
13,961
7,831
7,831
14,452
14,452
13,042
13,042
10,922
10,92213,04213,04214,45214,4527,8317,83113,96113,9615,7935,7935,0595,0593,3653,3651,1591,1592,7052,7051,1511,1511,3271,3271,3621,3629559551,6331,6331,1171,1174204205855770369
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
37
37
0
0
37
37
0
0
0
6,500
0
117
0
125
0
131
0
135
0
144
0
148
0
102
0
105
113
113105010201480144013501310125011706,50000037370037370000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
37
37
0
0
37
37
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000037370037370000000000
       Accounts payable 
173
0
306
384
384
384
990
990
1,499
1,499
770
770
1,158
1,158
1,030
1,030
868
868
2,279
2,279
690
690
2,748
2,784
4,344
4,344
4,986
4,986
4,329
13,326
7,088
7,088
3,450
13,668
12,161
12,161
9,986
9,98612,16112,16113,6683,4507,0887,08813,3264,3294,9864,9864,3444,3442,7842,7486906902,2792,2798688681,0301,0301,1581,1587707701,4991,4999909903843843843060173
       Other Current Liabilities 
0
0
0
201
0
37
90
127
134
134
149
186
204
204
260
297
0
284
0
425
0
353
0
456
0
585
0
672
0
491
0
595
0
681
0
776
823
823776068105950491067205850456035304250284029726020420418614913413412790370201000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
814
0
817
0
773
0
725
0
614
0
545
0
388
0
350
317
3173500388054506140725077308170814000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
814
0
749
0
683
0
617
0
451
0
375
0
288
0
140
0
01400288037504510617068307490814000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
68
68
89
89
108
108
163
163
76
76
100
100
113
113
0
01131131001007676163163108108898968680000000000000000000000
> Total Stockholder Equity
0
0
865
609
12,677
12,677
11,230
11,230
14,706
14,706
13,390
13,390
14,917
14,917
13,864
13,864
19,359
19,359
82,806
82,806
79,276
79,276
0
108,182
0
89,449
0
78,273
0
52,920
0
42,313
0
73,666
0
53,678
33,799
33,79953,678073,666042,313052,920078,273089,4490108,182079,27679,27682,80682,80619,35919,35913,86413,86414,91714,91713,39013,39014,70614,70611,23011,23012,67712,67760986500
   Common Stock
0
0
0
1,577
15,074
15,074
15,072
15,072
21,058
21,058
21,057
21,057
25,808
25,808
26,941
26,941
36,427
36,427
109,468
109,468
110,551
110,551
145,865
145,865
146,511
146,511
146,989
146,989
147,069
147,069
147,195
147,195
209,550
209,550
209,834
209,834
238,113
238,113209,834209,834209,550209,550147,195147,195147,069147,069146,989146,989146,511146,511145,865145,865110,551110,551109,468109,46836,42736,42726,94126,94125,80825,80821,05721,05721,05821,05815,07215,07215,07415,0741,577000
   Retained Earnings Total Equity0000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
800
0
0
0
1,250
0
0
0
2,339
0
0
0
4,073
0
4,030
0
3,585
0
4,774
0
6,512
0
7,668
0
9,133
0
8,439
0
7,358
7,440
7,4407,35808,43909,13307,66806,51204,77403,58504,03004,0730002,3390001,2500008000000000
   Capital Surplus 0000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
749
0
749
0
0
1,108
1,108
1,250
1,250
1,600
1,600
2,031
-308
2,440
2,440
4,073
4,073
4,030
4,030
3,585
3,585
4,774
4,774
6,512
6,512
7,668
7,668
9,133
9,133
8,439
8,439
7,358
-429
0
0-4297,3588,4398,4399,1339,1337,6687,6686,5126,5124,7744,7743,5853,5854,0304,0304,0734,0732,4402,440-3082,0311,6001,6001,2501,2501,1081,108007490749000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue47
Cost of Revenue-19
Gross Profit2828
 
Operating Income (+$)
Gross Profit28
Operating Expense-60,066
Operating Income-51,894-60,039
 
Operating Expense (+$)
Research Development52,679
Selling General Administrative6,565
Selling And Marketing Expenses823
Operating Expense60,06660,066
 
Net Interest Income (+$)
Interest Income406
Interest Expense-16
Other Finance Cost-997
Net Interest Income1,386
 
Pretax Income (+$)
Operating Income-51,894
Net Interest Income1,386
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-51,910-58,636
EBIT - interestExpense = -51,910
-58,952
-51,894
Interest Expense16
Earnings Before Interest and Taxes (EBIT)-51,894-51,894
Earnings Before Interest and Taxes (EBITDA)-51,894
 
After tax Income (+$)
Income Before Tax-51,910
Tax Provision-0
Net Income From Continuing Ops-51,910-51,910
Net Income-51,910
Net Income Applicable To Common Shares-51,910
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses60,085
Total Other Income/Expenses Net6,742-1,386
 

Technical Analysis of Paradigm Biopharmaceuticals Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Paradigm Biopharmaceuticals Ltd. The general trend of Paradigm Biopharmaceuticals Ltd is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Paradigm Biopharmaceuticals Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Paradigm Biopharmaceuticals Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.335 < 0.335 < 0.335.

The bearish price targets are: 0.265.

Tweet this
Paradigm Biopharmaceuticals Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Paradigm Biopharmaceuticals Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Paradigm Biopharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartParadigm Biopharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Paradigm Biopharmaceuticals Ltd. The current adx is .

Paradigm Biopharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartParadigm Biopharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily Stochastic Oscillator ChartParadigm Biopharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartParadigm Biopharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartParadigm Biopharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily Williams %R ChartParadigm Biopharmaceuticals Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily Average True Range (ATR) ChartParadigm Biopharmaceuticals Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartParadigm Biopharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd Daily Money Flow Index (MFI) ChartParadigm Biopharmaceuticals Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Paradigm Biopharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Paradigm Biopharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Paradigm Biopharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.290
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Paradigm Biopharmaceuticals Ltd with someone you think should read this too:
  • Are you bullish or bearish on Paradigm Biopharmaceuticals Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Paradigm Biopharmaceuticals Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Paradigm Biopharmaceuticals Ltd

I send you an email if I find something interesting about Paradigm Biopharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Paradigm Biopharmaceuticals Ltd.

Receive notifications about Paradigm Biopharmaceuticals Ltd in your mailbox!